Patients who met | Total | PEG-IFN alfa-2a | PEG-IFN alfa- 2b | P* |
---|---|---|---|---|
80/80/80 rule | ||||
Genotype 1, n (%) | 286 | 171 (59.8) | 115 (40.2) | 0.45 |
Age, years† | 49 ± 11 | 48 ± 11 | 49 ± 11 | 0.52 |
BMI (Kg/m2) † | 24.6 ± 3.1 | 24.8 ± 3.2 | 24.3 ± 2.9 | 0.29 |
ALT (IU/L) † | 100 ± 81 | 103 ± 80 | 97 ± 84 | 0.51 |
HCV RNA (IU/mL) † | 3.7×106±1.6×106 | 2.4×106±1.5×106 | 5.6×106±2.2×106 | 0.15 |
F3-4 Fibrosis stage, n (%) § | 29/94 (30.9) | 26/75 (34.7) | 3/19 (15.8) | 0.17 |
Genotype 2/3, n (%) | 185 | 107 (57.8) | 78 (42.2) | |
Age, years† | 49 ± 12 | 48 ± 12 | 50 ± 11 | 0.16 |
BMI (Kg/m2) † | 23.9 ± 2.7 | 24.3 ± 3.1 | 23.6 ± 2.4 | 0.16 |
ALT (IU/L) † | 97 ± 94 | 101 ± 88 | 94 ± 88 | 0.51 |
HCV RNA (IU/mL) † | 1.8×106±1.5×106 | 1.6×106±1.2×106 | 2.1×106±1.4×106 | 0.49 |
F3-4 Fibrosis stage, n (%)‡ | 11/63 (17.5) | 7/51 (13.7) | 4/12 (33.3) | 0.19 |
Genotype others, n (%) | 9 (1.9) | 6 (2.1) | 3 (1.5) | |
Propensity score matched patients | Total | PEG-IFN alfa-2a | PEG-IFN alfa- 2b | P* |
Genotype 1, n (%) | 248 | 124 | 124 | 0.45 |
Age, years† | 50 ± 11 | 51 ± 11 | 50 ± 11 | 0.43 |
Gender (male), n (%) | 148 (59.7) | 112 (65.5) | 74 (64.3) | 0.90 |
BMI (Kg/m2) † | 24.4 ± 3.2 | 24.7 ± 3.2 | 24.3 ± 3.3 | 0.38 |
ALT (IU/L) † | 93 ± 76 | 95 ± 74 | 92 ± 79 | 0.83 |
HCV RNA (IU/mL) † | 3.0×106±1.3×106 | 2.5×106±1.3×106 | 3.6×106±1.1×106 | 0.31 |
F3-4 Fibrosis stage, n (%) # | 22/73 (30.1) | 18/50 (36.0) | 4/23 (18.2) | 0.17 |
Genotype 2/3, n (%) | 150 | 75 | 75 | |
Age, years† | 50 ± 11 | 48 ± 12 | 50 ± 11 | 0.16 |
Gender (male), n (%) | 81 (54.0) | 162 (61.8) | 108 (62.1) | 0.96 |
BMI (Kg/m2) † | 23.9 ± 2.9 | 24.3 ± 3.1 | 23.6 ± 2.4 | 0.16 |
ALT (IU/L) † | 89 ± 76 | 101 ± 88 | 94 ± 88 | 0.51 |
HCV RNA (IU/mL) † | 1.7×106±1.4×106 | 1.6×106±1.2×106 | 2.1×106±1.4×106 | 0.49 |
F3-4 Fibrosis stage, n (%)§ | 10/46 (21.7) | 6/34 (17.6) | 4/12 (33.3) | 0.42 |